Thus, further studies are warranted to determine whether SF, transferrin, and Hb reduction may improve the HU risk factors, and thereby reduce the risk of developing gout, diabetes mellitus, cardiovascular diseases, nonalcoholic fatty liver disease, and cancer. Here, GSTM1 is linked to metabolic dysfunction-associated steatotic liver disease.